A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that certain mutations in the individual cancer genomes will
predict response to Everolimus therapy. To identify possible genetic mutations that affect
tumor response to Everolimus the investigators will obtain sequence analysis of tumors from
all patients that will be treated with Everolimus in this study. Moreover, the investigators
performed a systematic review of the currently available data to identify mutations that
could be predictive for increased mTOR activity in cancer cells. These mutations have been
described to lead to mTOR activation but their predictive value for response to Everolimus
therapy remains unclear. The investigators will use the data generated in the investigators
own prospective treatment study and the data from literature to select patients for entry
into a second part of this trial. In this part the investigators want to test the hypothesis
that selecting patients based on their specific genetic mutations increases the likelihood of
response.